MaxCyte, Inc.
MXCT
Rank in Stocks
#18411
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes... MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Share Price
$1.30
Last synced: 2026-11-09
Market Cap
$134.17M
Change (1 day)
3.17%
Change (1 year)
-16.13%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MaxCyte, Inc. (MXCT)
Category
Healthcare
Operating Margin for MaxCyte, Inc. (MXCT)
Operating Margin as of November 2026 TTM: -111.63%
According to MaxCyte, Inc.'s latest financial reports, its current operating margin (TTM) is -111.63%. At the end of 2025 the company had an operating margin of -137.12%.
Operating Margin history for MaxCyte, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -111.63% | -18.59% |
| 2025 | -137.12% | 3.46% |
| 2024 | -132.54% | 13.30% |
| 2023 | -116.98% | 89.23% |
| 2022 | -61.82% | 15.21% |
| 2021 | -53.66% | 27.01% |
| 2020 | -42.25% | -26.44% |
| 2019 | -57.44% | 13.63% |
| 2018 | -50.55% | -23.92% |
| 2017 | -66.44% | 199.28% |
| 2016 | -22.20% | 171.06% |
| 2015 | -8.19% | -54.01% |
| 2014 | -17.81% | 50.55% |
| 2013 | -11.83% | -69.50% |
| 2012 | -38.79% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.35% |
US
|
|
| -149.01% | -98.67% |
US
|
|
| 25.57% | -100.23% |
AU
|
|
| 31.23% | -100.28% |
BE
|
|
| 29.35% | -100.26% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MaxCyte, Inc.'s operating margin
What is MaxCyte, Inc.'s operating margin?
MaxCyte, Inc.'s operating margin is -111.63%, as of Nov 2026.
What was MaxCyte, Inc.'s operating margin in 2025?
In 2025, MaxCyte, Inc.'s operating margin was -137.12%, compared with -132.54% in 2024.
How has MaxCyte, Inc.'s operating margin changed since 2020?
From 2020 to 2025, MaxCyte, Inc.'s operating margin was highest in 2020 (-42.25%) and lowest in 2025 (-137.12%).
How does MaxCyte, Inc.'s operating margin compare with similar companies?
MaxCyte, Inc.'s operating margin (-111.63%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.